KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline ...

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on ...

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PI ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Amgen (AMGN) announced on Monday that a late-stage study evaluating its Bemarituzumab in combination with chemotherapy met ...

Persistent Corneal Epithelial Defects (PCEDs) occur when the corneal epithelium fails to re-epithelialize and close within 10-14 days following an injury, despite standard treatment.

A combination of eyelid pressure patching and decellularized, dehydrated pure amniotic membrane basement membrane healed persistent corneal epithelial defects, according to a study published in ...

Complete success was defined as improvement in corneal surface integrity (decrease in epithelial defect or decrease in corneal surface staining if no defect at baseline).

Corneal epithelial defects were either stable or improved, with patients 1, 2, and 3 achieving grade 0 (no defect) by week 52, while patient 4 remained at grade 1.

Did you know that certain medications can cause symptom of 'Corneal epithelium defect'. Find these drugs listed on the page and be warned of similar symptoms as possible side-effects.